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ole of Inotropic Therapy*
. William Dec, MD, FACC
oston, Massachusetts
cute decompensated heart failure is among the most
ommon indications for hospitalization in the U.S. and
esults in approximately one million hospitalizations annu-
lly (1). Although consensus guidelines provide evidence-
ased strategies for the treatment of chronic heart failure,
he current therapy of acute heart failure is largely empirical.
he first priority of management is relief of symptoms. A
ariety of studies have shown consistent correlations be-
ween improvement in resting hemodynamics, particularly
he reduction of elevated filling pressures, and improved
ymptom status during hospitalization and beyond (2).
ntravenous vasodilators and positive inotropic agents both
cutely lower filling pressures and enhance cardiac output.
lthough both drug classes are often viewed as “corner-
tones” of treatment, considerable controversy exists about
heir relative benefits during hospitalization.
See page 57
In this issue of the Journal, Abraham et al. (3) help clarify
he role of intravenous vasoactive therapy for inpatient
anagement of acute decompensated heart failure. The
uthors performed a retrospective observational analysis
sing data from the Acute Decompensated Heart Failure
ADHERE) national registry, which was designed to pro-
pectively collect information on heart failure hospitaliza-
ions and clinical outcomes. More than 65,000 admissions
ere analyzed; patients who received either intravenous
asodilator therapy (nitroglycerin or nesiritide) or inotropic
herapy (dobutamine or milrinone) were compared. The
rincipal finding of the study was that short-term vasodila-
or therapy was associated with significantly lower in-
ospital mortality than positive inotropic treatment. A
ropensity score analysis was performed for each pair-wise
omparison to adjust for potentially confounding differences
n baseline clinical and demographic characteristics between
reatment groups. This propensity score has been previously
alidated to produce relatively unbiased estimates of treat-
ent effect in observational studies. Unadjusted in-hospital
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.o
From the Cardiology Division, Massachusetts General Hospital, Boston,
assachusetts.ortality varied widely, ranging from 4.1% for the entire
ohort to as much as 14% for patients who received
ntravenous inotropes. Patients treated with either nitro-
lycerin or nesiritide had intermediate mortality rates of
.7% to 7.1%. Adjusted inpatient mortality odds ratios of
.59 and 0.47 were observed for nesiritide versus milrinone
r dobutamine, respectively. Similarly, adjusted inpatient
ortality odds ratios of 0.69 and 0.46 were noted for
itroglycerin therapy versus milrinone or dobutamine, re-
pectively. Mortality did not differ between nesiritide and
itroglycerin therapy.
The impact of intravenous inotropic therapy during
ospitalization recently has been investigated in two ran-
omized controlled trials. In the Outcomes of a Prospective
rial of Intravenous Milrinone for Exacerbation of Chronic
eart Failure (OPTIME-CHF), Cuffe et al. (4) randomly
ssigned 951 hospitalized patients to a 48-h infusion of
ntravenous milrinone or placebo. The administration of
ilrinone was associated with a higher rate of early treat-
ent failure, more sustained hypotension, and new atrial
rrhythmias. A nonsignificant but higher number of deaths
lso was observed (3.8% vs. 2.3%, p  0.19). The calculated
n-hospital mortality odds ratio for placebo versus milrinone
n the OPTIME-CHF study was 0.61, which is almost
dentical to the ADHERE study investigators’ findings.
urther, in-hospital use of milrinone was associated with a
rend toward higher 60- day mortality. Felker et al. (5)
eported a significant interaction between heart failure
tiology and outcome. Patients with an ischemic etiology
hat were treated with milrinone had a higher 60-day
ortality (11.6%) than that observed in the nonischemic
roup (7.5%; p 0.03) and a higher composite rate of death
r rehospitalization (42% vs. 35%; p  0.01). The authors
onclude that milrinone should not be used routinely for
atients with an exacerbation of heart failure (5).
The effect of nesiritide and dobutamine on short-term
utcomes in acute heart failure was reported recently in an
pen-label, randomized, controlled trial by Silver et al. (6).
emodynamically unstable patients who required immedi-
te inotropic or vasopressor support or whose initial systolic
lood pressure fell to 90 mm Hg were excluded from the
rial. Although no difference was noted in hospital length of
tay, a trend toward fewer readmissions was observed for
esiritide treatment. Importantly, six-month mortality was
ower for patients treated with low-dose nesiritide (18%)
ompared with those treated with dobutamine (31%) (6).
hese two trials teach the important lesson that even
hort-term exposure to positive inotropic agents that act by
ncreasing intracellular cyclic AMP during periods of acute
ecompensation increase risk after hospital discharge. This
onclusion is not entirely surprising; the myocardium is
urther stressed by markedly altered hemodynamics and
urther activation of neurohormones, cytokines, and
xygen-free radicals. Inotropic stimulation during a period
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Editorial Comment July 5, 2005:65–7schemia or apoptosis (7). This message is again reiterated
y the ADHERE study results.
The ADHERE study results should not be over-
nterpreted to conclude that milrinone and dobutamine have
o role in the contemporary treatment of acute heart failure.
lthough it is clear that their routine use is not warranted,
hese agents can be lifesaving for patients with rapidly progres-
ive hemodynamic collapse (2,7). Patients who present with
btundation, anuria, or lactic acidosis may only respond to
notropic therapy, which should be used until the cause of
hock is determined and definitive therapy implemented.
ohria et al. (2) have confirmed the utility of a two-minute
edside assessment of hemodynamic profiles for patients
ith advanced heart failure. The majority of patients en-
olled in clinical trials and virtually all patients in the
DHERE study had evidence for elevated filling pressures
nd preserved end-organ perfusion (“warm and wet” pro-
le). The optimum management for those individuals with
levated filling pressures and significant hypoperfusion re-
ains unknown. Many are unable to tolerate intravenous
asodilators and may, in theory, benefit from the transient
se of newer positive inotropic agents that increase contrac-
ility without enhancing intracellular cyclic AMP, such as
evosimedan and toborinone, which act by increasing myo-
brillar sensitivity to calcium (8).
More accurate risk profiling of hospitalized patients also
ay guide future treatment. Felker et al. (9) reported
redictors of a composite end point of death or rehospital-
zation within 60 days of hospital discharge were the
umber of previous hospitalizations for heart failure,
zotemia, lower systolic blood pressure, anemia, and a
istory of percutaneous coronary intervention.
The ADHERE study represents the largest hospitalized
opulation with decompensated heart failure to be studied
rospectively. Unlike clinical trials, the reported experience
epresents “real-world” contemporary management. It in-
ludes both systolic and diastolic etiologies of heart failure,
n older population than typically is enrolled in clinical
rials, a higher percentage of patients with diabetes, and a
arge percentage of patients with impaired renal function.
mportantly, although the focus of this study was a com-
arison of intravenous vasoactive agents, it should be noted
hat more than 75% of the patients were treated with
nhanced diuretic therapy alone.
Despite its considerable strengths, several limitations
eed to be acknowledged. The study was uncontrolled and
bservational in nature. Despite careful and statistically
alidated methodologies, it remains possible that severity of
llness was not adequately controlled for by risk adjustment
odeling. In addition, a surprisingly small percentage of
atients were receiving vasodilators at study entry
angiotensin-converting enzyme inhibitors, 44%; angioten-
in receptor blockers, 12%). Although few patients pre-
ented with de novo heart failure, it remains possible that
he observed beneficial effects of intravenous vasodilators
ay have been greater than that routinely achievable whencute heart failure develops despite maximal oral vasodilator
herapy. Finally, milrinone or dobutamine may have been
reserved” for patients who failed to respond to more
onventional therapies. Median time to initiation of diuretic
herapy was 9.5 h, 15.9 h for nitroglycerin, 30 h for
esiritide, 46 h for dobutamine, and 54 h for milrinone. It
s conceivable that positive inotropic agents were viewed as
rugs of last resort. It is also possible that the delay in
nitiating these drugs may have contributed to worse survival.
linical implications. The treatment of acute decom-
ensated heart failure among hospitalized patients should
egin initially with increased diuretics. Most patients
70%) will respond to this treatment alone. For the
inority of patients in whom intravenous vasoactive
herapy is considered, vasodilator treatment using nitro-
lycerin, nesiritide, or possibly nitroprusside (which was
ot evaluated), appears to be the safest and most effective
reatment option for patients who lack hemodynamic
ompromise. Intravenous inotropic support should be
eserved for those patients with marked hemodynamic
ompromise, cardiogenic shock, or evidence for end-
rgan hypoperfusion. The optimum treatment for pa-
ients with cardiorenal syndromes and those identified as
high risk” remains to be determined. Although observa-
ional studies such as ADHERE study are useful in
ssessing current therapeutic practices, there is an urgent
eed for controlled trials in this growing patient popu-
ation. Future practice guidelines for treatment of acute
eart failure must be based upon more complete under-
tanding of its pathophysiology and an evidence-based
pproach substantiated by prospective controlled trials.
opefully, the treatment of acute decompensated heart
ailure during the next decade will become as rigorously
efined as current outpatient therapy of the chronic heart
ailure syndrome.
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ardiology Division, Massachusetts General Hospital, Bigelow
00, Mailstop 847, Fruit Street, Boston, Massachusetts 02114.
-mail: gdec@partners.org.
EFERENCES
. Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the
evaluation and management of chronic heart failure in the adult:
executive summary: a report of the American College of Cardiology/
American Heart Association Task Force on Practice Guidelines (Com-
mittee to Revise the 1995 Guidelines for the Evaluation and Manage-
ment of Heart Failure). Circulation 2001;104:2996–3007.
. Nohria A, Lewis E, Stevenson LW. Medical management of advanced
heart failure. JAMA 2002;287:628–40.
. Abraham WT, Adams KF, Fonanow GC, et al., for the ADHERE
Scientific Advisory Committee and Investigators, and the ADHERE
Study Group. In-hospital mortality in patients with acute decompen-
sated heart failure requiring intravenous vasoactive medications: an
analysis from the Acute Decompensated Heart Faliure National Reg-
istry (ADHERE) registry. J Am Coll Cardiol 2005;46:57–64.
. Cuffe MS, Califf RM, Adams KF, et al., for the Outcomes of a
Prospective Trial of Intravenous Milrinone for Exacerbations of





67JACC Vol. 46, No. 1, 2005 Dec
July 5, 2005:65–7 Editorial Commentintravenous milrinone for acute exacerbation of chronic heart failure: a
randomized controlled trial. JAMA 2002;287:1541–7.
. Felker GM, Benza RL, Chandler AB, et al., for the OPTIME-CHF
Investigators. Heart failure etiology and response to milrinone in
decompensated heart failure. Results from the OPTIME-CHF study.
J Am Coll Cardiol 2003;41:997–1003.
. Silver MA, Horton DP, Ghali JK, Elkayam U. Effect of nesiritide versus
dobutamine on short-term outcomes in the treatment of patients with
acutely decompensated heart failure. J Am Coll Cardiol 2002;39:798–803.. Stevenson LW. Clinical use of inotropic agents for heart failure: looking
backward or forward: part I: inotropic infusions during hospitalization.
Circulation 2003;108:367–72.
. Packer M, Nienimen MS, Hassenfuss G. Effects of intravenous
levosimendan, a calcium sensitizer, on survival of hospitalized patients
with acute heart failure. Circulation 1999;100 Suppl I:I–646.
. Felker GM, Leimberger JD, Califf RM, et al. Risk stratification after
hospitalization for decompensated heart failure. J Card Fail 2004;10:
460–6.
